Analyst Soumit Roy of JonesTrading maintained a Buy rating on Precision BioSciences, retaining the price target of $30.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Soumit Roy has given his Buy rating due to a combination of factors that highlight Precision BioSciences’ promising developments in their clinical pipeline. The company is making significant progress with its PBGENE-HBV program for chronic Hepatitis B, as evidenced by the upcoming presentation of new data at the AASLD 2025 conference. The data from the Phase 1 ELIMINATE-B trial has shown encouraging antiviral activity, with notable reductions in Hepatitis B surface antigen levels and no severe adverse effects reported.
Additionally, Precision BioSciences is advancing its second asset, PBGENE-DMD, aimed at treating Duchenne Muscular Dystrophy, with plans to file an IND/CTA application by the end of 2025. The strategic move to initiate clinical trials for this asset in 2026 further underscores the company’s commitment to expanding its therapeutic portfolio. These developments, coupled with the company’s robust research efforts, have led to a positive outlook on the stock, justifying the Buy rating.
In another report released on October 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.
DTIL’s price has also changed moderately for the past six months – from $5.010 to $6.640, which is a 32.53% increase.